What's the Problem? Cultural Capability and Learning from Historical Performance

Contains the cis-eQTLs with P value < 5 % for T-cells obtained from early undifferentiated arthritis patients. (TXT 1162 kb

MOESM4 of Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis

Additional file 4: Table S3. Complete Nanostring dataset

MOESM1 of Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis

Additional file 1: Table S1. List of reagents used for flow cytometry analysis

MOESM3 of Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis

Additional file 3: Table S2. Differentially expressed genes in T cells co-cultured with or without tolDC or imDC

MOESM2 of Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis

Additional file 2: Figure S1. Inflammatory arthritis (IA) patients have CD4+ T-cells responding to one or more HSP-peptides. Cell proliferation dye (CFSE/CTV)-labelled PBMC of healthy controls and IA patients were cultured with pan-DR-binding HSP peptides: DnaJP1, HSP60p1, HSP60p2 and B29 for 9 days. Percentage of CFSE/CTV-negative live CD4+ T-cells was measured using flow cytometry. The graph depicts the percentage of donors that responds to 1, 2, 3 or all 4 HSP-peptides

Additional file 6: of Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23

Contains the cis-eQTLs with P value < 5 % for B-cells obtained from early undifferentiated arthritis patients. (TXT 985 kb

Additional file 2: of Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23

Contains the cis-eQTLs with P value < 5 % for CD4+ T-cells obtained from NRHV participants. (TXT 405 kb

Appendices 2:

Informed consent form for additional blood. (PDF 102 kb

Additional file 4: of Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents. (DOCX 54 kb

Appendices 3:

Additional information. (DOCX 23 kb